Inovio To Independently Develop Prostate Cancer Immunotherapy - Quick Facts

(RTTNews) - Inovio Pharmaceuticals, Inc. (INO) Monday announced that it has terminated its 2013 collaboration, option, and license agreement with Swiss pharmaceutical giant Roche Holding AG (RHHBY.PK, ROG.SW, RO.SW) to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer.

Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.

All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio.

However, Inovio and Roche will continue to collaborate and co-develop Inovio's DNA immunotherapy, INO-1800, against hepatitis B virus under their existing license agreement. The partnership is on track to move INO-1800 collaboratively into a phase I study in 2015.